Marksans Pharma is at the forefront of the pharmaceutical industry, distinguished by a customer-centric approach. Specializing in Over-the-Counter (OTC) and prescription drugs, the company has cultivated a strong presence in highly regulated markets. Leveraging robust Research and Development (R&D) capabilities and advanced manufacturing facilities both domestically and internationally, the company is among the top five Indian Companies in the United Kingdom. The company’s strategic emphasis on optimizing supply chain efficiencies has facilitated substantial business expansion across key global markets. The company’s high-quality and expansive portfolio has led to a growing foothold in the USA as well.

Headquartered in Mumbai, the company has built a robust global footprint, actively operating in over several countries worldwide. The company’s integrated business approach, supported by a talented workforce, positions it for sustained long-term growth with a focus on value creation. The company’s key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Pain Management, Cough and Cold, Digestives, CVS, CNS Oncology, Antidiabetic, and Antibiotics, among others.

At the core of its operations is an unwavering commitment to quality. Rigorous Quality Control (QC) and Quality Assurance (QA) processes have positioned it as a niche player in the pharmaceutical ecosystem. Adherence to Current Good Manufacturing Practices (cGMP) norms is integral to its operations. Continuous improvement initiatives across products, processes, and skills ensure its offerings evolve to meet changing client needs. The company’s world-class manufacturing facilities have garnered approval from esteemed institutions such as the US FDA, UK MHRA, Australian TGA, and other foreign health authorities.

Business area of the company 

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.

Formulations business product portfolio

• Tablets (plain, enteric-coated and film-coated)
• Hard capsules
• Soft gelatin capsules
• Oral liquids
• Ointments

Consumer Self-Care Products

• Pain Management - Arthritis
• Upper Respiratory - Cough & Cold and Allergy
• Digestive Health
• VMS (Vitamins Minerals and Supplements)
• Skin Care Products

Prescription - Rx Therapeutic Segments

• Cardiovascular System (CVS)
• Central Nervous System (CNS)
• Oncology
• Anti-Diabetics
• Anti-Biotic

Milestones

• 2001: Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.
• 2003: Spun off into a separate entity – Glenmark Laboratories Ltd. 
• 2003: Changed its name to ‘Marksans Pharma Ltd’
• 2005: Acquired Nova Pharmaceuticals Australasia Pty Ltd
• 2007: Acquired Bell, Sons & Co. (Druggists) Ltd. UK
• 2008: Acquired Relonchem Ltd. UK
• 2009: Marksans Pharma establlished itself as a global player
• 2015: Acquired TimeCapLaboratories Inc. USA
• 2017: Increased focus on OTC segment in US market
• 2022: Acquired Access Healthcare Dubai
• 2023: Raised Rs 372.40 crore in equity via conversion of warrants issued to OrbiMed and Promoters. 
• 2023: Acquired a manufacturing facility from Tevapharm India.
• 2024: Marksans crossed Rs 2,000 crore revenue.
• 2026: Incorporated two new wholly owned subsidiary companies by name Marksans Pharma (Europe) and Marksans (Canada) Inc.